Moderna, Inc. (MRNA)

147.13
13.00 8.10
NASDAQ
Prev Close 160.07
Open 153.47
Day Low/High 138.17 / 154.85
52 Wk Low/High 117.34 / 497.49
Volume 12.07M
Exchange NASDAQ
Shares Outstanding 405.45B
Market Cap 67.92B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Caution Signs, Laboring Labor Market, Gold Watch and Ugly Intel: Market Recon

Caution Signs, Laboring Labor Market, Gold Watch and Ugly Intel: Market Recon

Plus, why shares of vaccine maker Moderna are taking a hit.

A Complete Review of the Past Week's Macroeconomic Developments

Here is a summary of this week's major macroeconomic events:  The Positives  1) Moderna , while still having to progress thru phase 3 trials, reported positive antibody results from phase 1 data and brings us a step closer to that hoped for vaccine....

Jim Cramer: An Analyst's Dream

Jim Cramer: An Analyst's Dream

All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.

Small Caps Make Some Big Noise

Small Caps Make Some Big Noise

FAANG stocks lag while the Russell rises, bringing divergences and questions.

Treasury Yields Post-Covid, Reading Fed Tea Leaves and Junk Bond Intrigue

Treasury Yields Post-Covid, Reading Fed Tea Leaves and Junk Bond Intrigue

A Fed governor speaks of accommodation, and AMC Entertainment's bond maneuvers serve as a warning to those who swim in the high-yield pool.

The Only Certainty Is the Lack of Certainty

* Much like the Wild West, the market's action has turned unpredictable and volatile -- with little of a thematic character, save trading within a defined range and with some outstanding (and speculative) characters. The encouraging announcement of ...

An Ugly Intraday Reversal Turns Into a Bear Trap

An Ugly Intraday Reversal Turns Into a Bear Trap

Stock picking continues to be the most productive approach as market timers are battered and bruised once again.

Jim Cramer: How Do You Refute These Market Gains?

Jim Cramer: How Do You Refute These Market Gains?

This is pretty much exactly what you get when you have so much positive research.

Moderna Rated New Buy at Jefferies

Novavax and Its $1.6 Billion Award Just Got My Attention

Novavax and Its $1.6 Billion Award Just Got My Attention

The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.

Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers

Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers

What if the market is simply pricing in a quarter that had already been priced out?

I Wouldn't Buy Pfizer Shares on This Pop

I Wouldn't Buy Pfizer Shares on This Pop

I would wait until the next down day, and there will be one.

Covid-19 Complications, Grocery Store-y, More on Moderna: Market Recon

Covid-19 Complications, Grocery Store-y, More on Moderna: Market Recon

Plus, a closer look at Thursday's late-day rally and at actions impacting the nation's big banks.

Tesla Shares May Power Down a Bit Near Term

Tesla Shares May Power Down a Bit Near Term

The charts of the electric vehicle maker are showing some weakening in the stock, though a major shake-out isn't likely.

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?

Jim Cramer: Is the Market More Dangerous Because of 3 New Constituencies?

Jim Cramer: Is the Market More Dangerous Because of 3 New Constituencies?

I can't educate the foreign investors. The professional mutual fund managers think I'm dead wrong. But I can help teach the new retail traders.

Here's How I'm Actively Managing Assets

Here's How I'm Actively Managing Assets

This market is offering trading opportunities the likes of which haven't been seen since early 2009.

Risky Business, Painful Recovery, Trading Thoughts

Risky Business, Painful Recovery, Trading Thoughts

The massive tock market drop was to be expected, and seasoned traders were prepared for it. But there was also some good news on the coronavirus vaccine/treatment front.

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.

Rioting in the Streets, Retail Response, Trading Thoughts

Rioting in the Streets, Retail Response, Trading Thoughts

Let's hope that the violence subsides, the valid voices of peaceful protesters are heard, and the lack of social distancing protocols does not lead to a resurgence in the spread of the virus.

Strong Rebound From Covid-19 Meltdown Turns Bargain Hunting Into a Challenge

Strong Rebound From Covid-19 Meltdown Turns Bargain Hunting Into a Challenge

A now-overbought market leaves few values available among equities.

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

Perception Continues to Drive the Market

Perception Continues to Drive the Market

The negatives are being shaken off like a first time rider on a long-time bull which means long remains the name of the game.

Merck Is All In With a Threefold Approach to Covid-19

Merck Is All In With a Threefold Approach to Covid-19

I've been long Merck for a long time, since way before this pandemic became part of our lives.

Floor Traders Return to NYSE, Novavax Vaccine News, Be Amphibious

Floor Traders Return to NYSE, Novavax Vaccine News, Be Amphibious

The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.

Jim Cramer: Why Is the Market Down? It's Simple

Jim Cramer: Why Is the Market Down? It's Simple

The market may be down but, once again, the decline's about the White House getting re-tough on China.